BlackRock
TCRX icon

BlackRock’s TScan Therapeutics TCRX Stock Holding History

BlackRock’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.86M Sell
1,840,952
-7,743
-0.4% -$8.27K ﹤0.01% 4146
2025
Q4 		$1.85M Sell
1,848,695
-534,069
-22% -$773K ﹤0.01% 4138
2025
Q3 		$4.34M Sell
2,382,764
-183,760
-7% -$325K ﹤0.01% 3838
2025
Q2 		$3.72M Sell
2,566,524
-2,312,309
-47% -$3.34M ﹤0.01% 3884
2025
Q1 		$6.73M Sell
4,878,833
-82,867
-2% -$179K ﹤0.01% 3509
2024
Q4 		$15.1M Buy
4,961,700
+328,824
+7% +$1.49M ﹤0.01% 3210
2024
Q3 		$23.1M Buy
4,632,876
+170,524
+4% +$1.03M ﹤0.01% 2941
2024
Q2 		$26.1M Buy
4,462,352
+2,763,139
+163% +$21.8M ﹤0.01% 2820
2024
Q1 		$13.5M Buy
1,699,213
+27,486
+2% +$173K ﹤0.01% 3192
2023
Q4 		$9.75M Sell
1,671,727
-8,722
-0.5% -$39.9K ﹤0.01% 3409
2023
Q3 		$4.3M Buy
1,680,449
+416,996
+33% +$973K ﹤0.01% 3710
2023
Q2 		$3.16M Sell
1,263,453
-251,597
-17% -$675K ﹤0.01% 3880
2023
Q1 		$3.18M Buy
1,515,050
+1,104
+0.1% +$2.62K ﹤0.01% 3836
2022
Q4 		$2.35M Buy
1,513,946
+131
+0% +$321 ﹤0.01% 4069
2022
Q3 		$4.62M Sell
1,513,815
-1,149
-0.1% -$3.76K ﹤0.01% 3791
2022
Q2 		$4.76M Sell
1,514,964
-4,224
-0.3% -$11.6K ﹤0.01% 3837
2022
Q1 		$4.25M Buy
1,519,188
+20,650
+1% +$89.3K ﹤0.01% 4053
2021
Q4 		$6.74M Sell
1,498,538
-2,039
-0.1% -$14.7K ﹤0.01% 3873
2021
Q3 		$12.5M Buy
+1,500,577
New +$13.9M ﹤0.01% 3574

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

BlackRock's TCRX Position: Q1 2026 in Review

BlackRock reduced its TScan Therapeutics (TCRX) stake by 0.42% in Q1 2026, selling an estimated $8.27K and leaving 1,840,952 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #4146.

BlackRock first reported a position in TCRX in Q3 2021 and has held it in 19 quarters since. The position peaked at $26.1M in Q2 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • BlackRock held 1,840,952 shares of TScan Therapeutics worth $1.86M as of Q1 2026.
  • BlackRock sold 7,743 TScan Therapeutics shares in Q1 2026, an estimated $8.27K.
  • TScan Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4146 holding.
  • BlackRock first reported a position in TScan Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • BlackRock's TScan Therapeutics position peaked at $26.1M in Q2 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.